Shares of GENinCode Plc (LON:GENI – Get Free Report) shot up 8.7% during trading on Tuesday . The stock traded as high as GBX 0.98 and last traded at GBX 0.98. Approximately 3,765,810 shares traded hands during mid-day trading, a decline of 41% from the average daily volume of 6,361,748 shares. The stock had previously closed at GBX 0.90.
GENinCode Trading Up 8.7%
The stock has a 50-day moving average price of GBX 1.10 and a two-hundred day moving average price of GBX 1.45. The stock has a market cap of £7.09 million, a PE ratio of -0.42 and a beta of 0.59. The company has a debt-to-equity ratio of 117.74, a current ratio of 0.93 and a quick ratio of 15.88.
GENinCode (LON:GENI – Get Free Report) last announced its quarterly earnings results on Monday, June 8th. The company reported GBX (2.08) earnings per share for the quarter. GENinCode had a negative return on equity of 409.40% and a negative net margin of 185.47%.The business had revenue of GBX 308 million during the quarter. Sell-side analysts forecast that GENinCode Plc will post -7.1299999 earnings per share for the current fiscal year.
About GENinCode
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.
Featured Articles
- Five stocks we like better than GENinCode
- 3 Dividend Stocks Under $30 to Anchor Your Portfolio
- How Does D-Wave’s New Simulator Change the Quantum Computing Landscape?
- Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock
- The Biotech Sector Looks Ready for a Multi-Year Breakout—Here’s What to Watch.
Receive News & Ratings for GENinCode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENinCode and related companies with MarketBeat.com's FREE daily email newsletter.
